OBJECTIVE: To determine the response rate, duration of response and survival with weekly gemcitabine plus docetaxel in metastatic or unresectable pancreatic cancer. METHODS:Forty patients were enrolled, and 38 patients were evaluable forsurvival and toxicity. Thirty-seven patients were evaluable for response. Nine patients (24%) had locally advanced disease and 29 (76%) had metastatic disease at the time of enrollment. Median Eastern Cooperative Oncology Group performance status was 1. Patients received gemcitabine 750 mg/m(2) i.v. and docetaxel 35 mg/m(2) i.v. weekly for 3 out of 4 weeks for a maximum of 6 cycles. RESULTS: Patients received a median of 4 cycles (range 1-6) of chemotherapy. An objective response was obtained in 10 patients (27%) with a median duration of 17 weeks. Median survival was 7 months, and 1-year survival was 19.3%. Eight patients experienced at least one form of grade 4 toxicity and 27 patients experienced at least one type of grade 3 toxicity. CONCLUSIONS: The combination of gemcitabine and docetaxel is a well-tolerated regimen with clinical efficacy. The ultimate role of this combination versus single-agent gemcitabine can only be determined by a randomized phase III trial. Copyright 2003 S. Karger AG, Basel
RCT Entities:
OBJECTIVE: To determine the response rate, duration of response and survival with weekly gemcitabine plus docetaxel in metastatic or unresectable pancreatic cancer. METHODS: Forty patients were enrolled, and 38 patients were evaluable for survival and toxicity. Thirty-seven patients were evaluable for response. Nine patients (24%) had locally advanced disease and 29 (76%) had metastatic disease at the time of enrollment. Median Eastern Cooperative Oncology Group performance status was 1. Patients received gemcitabine 750 mg/m(2) i.v. and docetaxel 35 mg/m(2) i.v. weekly for 3 out of 4 weeks for a maximum of 6 cycles. RESULTS:Patients received a median of 4 cycles (range 1-6) of chemotherapy. An objective response was obtained in 10 patients (27%) with a median duration of 17 weeks. Median survival was 7 months, and 1-year survival was 19.3%. Eight patients experienced at least one form of grade 4 toxicity and 27 patients experienced at least one type of grade 3 toxicity. CONCLUSIONS: The combination of gemcitabine and docetaxel is a well-tolerated regimen with clinical efficacy. The ultimate role of this combination versus single-agent gemcitabine can only be determined by a randomized phase III trial. Copyright 2003 S. Karger AG, Basel
Authors: Christos Vaklavas; Apostolia-Maria Tsimberidou; Sijin Wen; David Hong; Jennifer Wheler; Chaan S Ng; Aung Naing; Cynthia Uehara; Robert A Wolff; Razelle Kurzrock Journal: Cancer Date: 2010-08-24 Impact factor: 6.860
Authors: A M Hamade; A Z Al-Bahrani; A M A Owera; A A Hamoodi; G H Abid; O I Bani Hani; S O'Shea; S H Lee; B J Ammori Journal: Surg Endosc Date: 2005-07-21 Impact factor: 4.584
Authors: Niranjan Awasthi; Changhua Zhang; Anna M Schwarz; Stefan Hinz; Changguang Wang; Noelle S Williams; Margaret A Schwarz; Roderich E Schwarz Journal: Carcinogenesis Date: 2013-06-26 Impact factor: 4.944
Authors: F Di Costanzo; P Carlini; L Doni; B Massidda; R Mattioli; A Iop; E Barletta; L Moscetti; F Recchia; P Tralongo; S Gasperoni Journal: Br J Cancer Date: 2005-07-25 Impact factor: 7.640